RU2018137496A3 - - Google Patents

Info

Publication number: RU2018137496A3
Authority: RU; Russia

Application number

RU2018137496A

Other versions

RU2018137496A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-25

Filing date

2017-03-24

Publication date

2020-04-27

2017-03-24 Application filed filed Critical

2020-04-27 Publication of RU2018137496A3 publication Critical patent/RU2018137496A3/ru

2020-04-27 Publication of RU2018137496A publication Critical patent/RU2018137496A/ru

2020-10-08 Application granted granted Critical

2020-10-08 Publication of RU2733975C2 publication Critical patent/RU2733975C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

RU2018137496A 2016-03-25 2017-03-24 Органические соединения RU2733975C2 (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662313629P	2016-03-25	2016-03-25
US62/313,629		2016-03-25
PCT/US2017/024137 WO2017165843A1 (en)	2016-03-25	2017-03-24	Organic compounds

Publications (3)

Publication Number	Publication Date
RU2018137496A3 true RU2018137496A3 (ru)	2020-04-27
RU2018137496A RU2018137496A (ru)	2020-04-27
RU2733975C2 RU2733975C2 (ru)	2020-10-08

Family

ID=59900860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018137496A RU2733975C2 (ru)	2016-03-25	2017-03-24	Органические соединения

Country Status (18)

Country	Link
US (5)	US10688097B2 (ru)
EP (2)	EP3407889B1 (ru)
JP (5)	JP6686168B2 (ru)
KR (2)	KR102684468B1 (ru)
CN (2)	CN108778277A (ru)
AU (1)	AU2017238842B2 (ru)
BR (1)	BR112018069594B1 (ru)
CA (1)	CA3016353C (ru)
DK (1)	DK3407889T3 (ru)
ES (1)	ES2879888T3 (ru)
HU (1)	HUE055334T2 (ru)
IL (5)	IL304192B2 (ru)
MX (2)	MX387700B (ru)
PL (1)	PL3407889T3 (ru)
PT (1)	PT3407889T (ru)
RU (1)	RU2733975C2 (ru)
SI (1)	SI3407889T1 (ru)
WO (1)	WO2017165843A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102372149B1 (ko)	2007-03-12	2022-03-07	인트라-셀룰라 써래피스, 인코퍼레이티드.	치환된 헤테로환 융합 감마-카르볼린 합성
JP2015514135A (ja)	2012-04-14	2015-05-18	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規組成物および方法
PT2968320T (pt)	2013-03-15	2021-01-28	Intra Cellular Therapies Inc	Compostos orgânicos
JP6475727B2 (ja)	2013-12-03	2019-02-27	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規方法
HUE065482T2 (hu)	2014-04-04	2024-05-28	Intra Cellular Therapies Inc	Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistái
PL3838274T3 (pl)	2016-01-26	2024-04-02	Intra-Cellular Therapies, Inc.	Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
WO2017165843A1 (en)	2016-03-25	2017-09-28	Intra-Cellular Therapies, Inc.	Organic compounds
JP2019510039A (ja)	2016-03-28	2019-04-11	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規組成物および方法
US11331316B2 (en)	2016-10-12	2022-05-17	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
WO2018175969A1 (en)	2017-03-24	2018-09-27	Intra-Cellular Therapies, Inc.	Novel compositions and methods
US11427587B2 (en)	2017-07-26	2022-08-30	Intra-Cellular Therapies, Inc.	Organic compounds
MX2020007271A (es)	2017-09-26	2020-08-17	Intra Cellular Therapies Inc	Sales y cristales novedosos.
MX2020009668A (es)	2018-03-16	2021-01-08	Intra Cellular Therapies Inc	Métodos novedosos.
JP2021519271A (ja) *	2018-03-23	2021-08-10	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
CN119613404A (zh)	2018-03-23	2025-03-14	细胞内治疗公司	有机化合物
IL279195B1 (en)	2018-06-06	2025-08-01	Intra Cellular Therapies Inc	A method of making bis-tosylate salt of lumateparone
WO2019237037A1 (en)	2018-06-08	2019-12-12	Intra-Cellular Therapies, Inc.	Novel methods
CA3106447A1 (en) *	2018-06-11	2019-12-19	Intra-Cellular Therapies, Inc.	Substituted heterocycle fused gamma-carbolines synthesis
JP2022500362A (ja) *	2018-08-29	2022-01-04	イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc.	新規組成物および方法
BR112021003655A2 (pt)	2018-08-31	2021-05-18	Intra-Cellular Therapies, Inc.	métodos novos
KR20210052472A (ko)	2018-08-31	2021-05-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
JP7520013B2 (ja)	2018-12-17	2024-07-22	イントラ－セルラー・セラピーズ・インコーポレイテッド	置換複素環縮合γ－カルボリンの合成
CN113227045B (zh)	2018-12-17	2024-04-26	细胞内治疗公司	取代的杂环稠合的γ-咔啉的合成
JP7487204B2 (ja) *	2018-12-17	2024-05-20	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
JP7649743B2 (ja)	2018-12-21	2025-03-21	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
EP3897643B1 (en)	2018-12-21	2023-11-15	Intra-Cellular Therapies, Inc.	A pyridopyrroloquinoxaline compound and its medical use
AU2020311894B2 (en)	2019-07-07	2025-06-26	Intra-Cellular Therapies, Inc.	Novel methods
JP2022549335A (ja)	2019-09-25	2022-11-24	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規方法
JP7261942B2 (ja)	2019-12-11	2023-04-20	イントラ－セルラー・セラピーズ・インコーポレイテッド	有機化合物
WO2022051770A2 (en) *	2020-09-04	2022-03-10	Intra-Cellular Therapies, Inc.	Novel salts, crystals, and co-crystals
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods
KR20250012110A (ko)	2022-05-18	2025-01-23	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규 방법
CN120417904A (zh)	2022-12-30	2025-08-01	细胞内治疗公司	作用于血清素5-HT2A受体的杂环稠合γ-咔啉
WO2024173901A1 (en)	2023-02-17	2024-08-22	Intra-Cellular Therapies, Inc.	Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en)	2023-11-22	2025-05-30	Intra-Cellular Therapies, Inc.	Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
US20250352469A1 (en)	2024-05-16	2025-11-20	Intra-Cellular Therapies, Inc.	Novel compositions, devices, and methods

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2490813A (en)	1944-11-29	1949-12-13	Standard Oil Co	Continuous process for making aryl amines
US3299078A (en)	1962-10-01	1967-01-17	Smith Kline French Lab	Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en)	1969-06-09	1974-05-28	J Sellstedt	Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3914421A (en)	1972-06-19	1975-10-21	Endo Lab	Pyridopyrrolobenzheterocycles for combatting depression
US4183936A (en)	1972-06-19	1980-01-15	Endo Laboratories, Inc.	Pyridopyrrolobenzheterocycles
US4238607A (en)	1972-06-19	1980-12-09	Endo Laboratories Inc.	Pyridopyrrolo benzheterocycles
IE41352B1 (en)	1974-04-01	1979-12-19	Pfizer	5-aryl-1,2,3,4-tetrahydro- -carbolines
US4001263A (en)	1974-04-01	1977-01-04	Pfizer Inc.	5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
US4136145A (en)	1974-07-05	1979-01-23	Schering Aktiengesellschaft	Medicament carriers in the form of film having active substance incorporated therein
US4155577A (en)	1978-06-12	1979-05-22	Raymond Edward L	Security device
US4219550A (en)	1978-11-09	1980-08-26	E. I. Du Pont De Nemours And Company	Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en)	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4530840A (en)	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH656884A5 (de)	1983-08-26	1986-07-31	Sandoz Ag	Polyolester, deren herstellung und verwendung.
JPS6067524A (ja)	1983-09-22	1985-04-17	Mitui Toatsu Chem Inc	超軟質ポリウレタンエラストマ−の耐熱性改良方法
US4849246A (en)	1985-10-09	1989-07-18	Wolfgang Schmidt	Process for producing an administration or dosage form for drugs, reagents or other active ingredients
JPH07110865B2 (ja)	1986-03-19	1995-11-29	クミアイ化学工業株式会社	チアジアゾロピリミジン−５−オン誘導体及び農園芸用殺菌剤
ES2058069T3 (es)	1986-04-07	1994-11-01	Kumiai Chemical Industry Co	Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
HU208484B (en)	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en)	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en)	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
DE4018247A1 (de)	1990-06-07	1991-12-12	Lohmann Therapie Syst Lts	Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
IT1271352B (it)	1993-04-08	1997-05-27	Boehringer Ingelheim Italia	Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CZ293764B6 (cs)	1993-11-19	2004-07-14	Janssen Pharmaceutica N. V.	Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
NZ282394A (en)	1994-03-02	1997-12-19	Akzo Nobel Nv	Dissolving tablets contain a dibenz[2,3:6,7] oxepino[4,5-c]pyrrole derivative for sublingual or buccal administration
ES2293638T3 (es)	1994-03-25	2008-03-16	Isotechnika, Inc.	Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en)	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
US5576460A (en)	1994-07-27	1996-11-19	Massachusetts Institute Of Technology	Preparation of arylamines
US5648542A (en)	1996-02-29	1997-07-15	Xerox Corporation	Arylamine processes
US5648539A (en)	1996-02-29	1997-07-15	Xerox Corporation	Low temperature arylamine processes
US5654482A (en)	1996-02-29	1997-08-05	Xerox Corporation	Triarylamine processes
US5847166A (en)	1996-10-10	1998-12-08	Massachusetts Institute Of Technology	Synthesis of aryl ethers
DE19646392A1 (de)	1996-11-11	1998-05-14	Lohmann Therapie Syst Lts	Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US5723669A (en)	1997-01-30	1998-03-03	Xerox Corporation	Arylamine processes
US5705697A (en)	1997-01-30	1998-01-06	Xerox Corporation	Arylamine processes
US5723671A (en)	1997-01-30	1998-03-03	Xerox Corporation	Arylamine processes
TWI242011B (en)	1997-03-31	2005-10-21	Eisai Co Ltd	1,4-substituted cyclic amine derivatives
US6323366B1 (en)	1997-07-29	2001-11-27	Massachusetts Institute Of Technology	Arylamine synthesis
GB2328686B (en)	1997-08-25	2001-09-26	Sankio Chemical Co Ltd	Method for producing arylamine
US6884429B2 (en)	1997-09-05	2005-04-26	Isotechnika International Inc.	Medical devices incorporating deuterated rapamycin for controlled delivery thereof
WO1999018057A1 (en)	1997-10-06	1999-04-15	Massachusetts Institute Of Technology	Preparation of diaryl ether by condensation reactions
ATE229499T1 (de)	1998-02-26	2002-12-15	Massachusetts Inst Technology	Metallkatalysierte arylierungen und vinylierungen von hydrazinen, hydrazonen, hydroxylaminen und oximen
US6235936B1 (en)	1998-02-26	2001-05-22	Massachusetts Institute Of Technology	Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en)	1998-05-07	1999-05-11	Xerox Corporation	Arylamine processes
US6395916B1 (en)	1998-07-10	2002-05-28	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
CA2336691C (en)	1998-07-10	2009-02-10	Massachusetts Institute Of Technology	Ligands for metals and metal-catalyzed processes
US7223879B2 (en)	1998-07-10	2007-05-29	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en)	1998-07-10	2001-10-23	Massachusetts Institute Of Technology	Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en)	1998-12-08	2001-07-19	Buchwald Stephen L.	Synthesis of aryl ethers
US6440710B1 (en)	1998-12-10	2002-08-27	The Scripps Research Institute	Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
CA2354472C (en)	1998-12-17	2009-02-24	Alza Corporation	Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6552024B1 (en)	1999-01-21	2003-04-22	Lavipharm Laboratories Inc.	Compositions and methods for mucosal delivery
NO309305B1 (no)	1999-02-19	2001-01-15	Norsk Hydro As	Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater
US6407092B1 (en)	1999-04-23	2002-06-18	Pharmacia & Upjohn Company	Tetracyclic azepinoindole compounds
US6376426B1 (en)	1999-04-23	2002-04-23	Basf Aktiengesellschaft	Herbicidal 3-(heterocycl-1-yl)-uracils
US7071186B2 (en)	1999-06-15	2006-07-04	Bristol-Myers Squibb Pharma Co.	Substituted heterocycle fused gamma-carbolines
MXPA01012969A (es)	1999-06-15	2003-10-14	Bristol Myers Squibb Pharma Co	Gamma-carbolinas fusionadas de heterociclo sustituido.
US6713471B1 (en)	1999-06-15	2004-03-30	Bristol-Myers Squibb Pharma Company	Substituted heterocycle fused gamma-carbolines
EP1104760B1 (en)	1999-12-03	2003-03-12	Pfizer Products Inc.	Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6541639B2 (en)	2000-07-26	2003-04-01	Bristol-Myers Squibb Pharma Company	Efficient ligand-mediated Ullmann coupling of anilines and azoles
RU2003121304A (ru)	2000-12-20	2005-01-27	Бристол-Маерс Сквибб Компани (Us)	Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en)	2000-12-20	2005-02-01	Bristol-Myers Squibb Company	Substituted pyridoindoles as serotonin agonists and antagonists
ATE298059T1 (de)	2001-03-26	2005-07-15	Hawle Armaturen Gmbh	Wanddurchführungssystem
EP2272813B1 (en)	2001-04-24	2016-11-16	Massachusetts Institute of Technology (MIT)	Copper-catalyzed formation of carbon-oxygen bonds
DE10123129A1 (de)	2001-05-02	2002-11-14	Berolina Drug Dev Ab Svedala	Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
ATE306486T1 (de)	2001-08-08	2005-10-15	Pharmacia & Upjohn Co Llc	Therapeutische 1h-pyrido(4,3-b)indole
US8900497B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for making a film having a substantially uniform distribution of components
US8900498B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en)	2001-10-12	2007-12-06	Fuisz Richard C	Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en)	2001-10-12	2008-04-15	Monosol Rx, Llc	Process for making an ingestible film
US8603514B2 (en)	2002-04-11	2013-12-10	Monosol Rx, Llc	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
EP1314554A1 (fr)	2001-11-23	2003-05-28	Kba-Giori S.A.	Dispositif de décollage d'éléments de sécurité
DE10162121A1 (de)	2001-12-12	2003-06-18	Berolina Drug Dev Ab Svedala	Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
NZ570198A (en)	2002-07-29	2010-01-29	Alza Corp	Methods and dosage forms for controlled delivery of paliperidone or risperidone
US6888032B2 (en)	2002-08-02	2005-05-03	Massachusetts Institute Of Technology	Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
US7223870B2 (en)	2002-11-01	2007-05-29	Pfizer Inc.	Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003287433A1 (en)	2002-11-01	2004-06-07	Oregon Health And Science University	Treatment of hyperkinetic movement disorder with donepezil
TW200413273A (en)	2002-11-15	2004-08-01	Wako Pure Chem Ind Ltd	Heavy hydrogenation method of heterocyclic rings
ES2364046T3 (es)	2002-12-19	2011-08-23	Bristol-Myers Squibb Company	Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina.
DE602004017325D1 (de)	2003-07-21	2008-12-04	Smithkline Beecham Corp	(2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl)-l-phenylalanylü-2-pyrrolidincarbonitril-p-toluolsulfonsäuresalz und wasserfreie kristalline formen davon
US7244734B2 (en)	2003-09-26	2007-07-17	Solvay Pharmaceuticals B.V.	Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
JP2005259113A (ja)	2004-02-12	2005-09-22	Ricoh Co Ltd	プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
WO2005095396A1 (en)	2004-03-05	2005-10-13	Pharma C S.A.	8-phenoxy-ϝ carboline derivatives
US20050222209A1 (en)	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en)	2004-04-14	2009-09-22	Bristol-Myers Squibb Company	Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
ATE506945T1 (de)	2004-09-20	2011-05-15	Sinai School Medicine	Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
WO2006032999A1 (en)	2004-09-21	2006-03-30	Pfizer Products Inc.	N-methyl hydroxyethylamine useful in treating cns conditions
US7614727B2 (en)	2004-09-30	2009-11-10	Fujifilm Corporation	Liquid ejection head, manufacturing method thereof, and image forming apparatus
BRPI0519054A2 (pt)	2004-12-15	2008-12-23	Hoffmann La Roche	fenil metanonas bi e tricÍclicas substituÍdas como inibidores de transportador i de glicina (glyt-1) para o tratamento de doenÇa de alzheimer
MX2007008903A (es)	2005-01-25	2007-09-07	Celgene Corp	Metodos y composiciones que usan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona.
WO2007025103A2 (en)	2005-08-23	2007-03-01	Intra-Cellular Therapies, Inc.	Organic compounds for treating reduced dopamine receptor signalling activity
AU2006299424A1 (en)	2005-10-06	2007-04-12	Auspex Pharmaceuticals, Inc.	Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
CN101370775A (zh)	2006-01-13	2009-02-18	惠氏公司	作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
US7750168B2 (en)	2006-02-10	2010-07-06	Sigma-Aldrich Co.	Stabilized deuteroborane-tetrahydrofuran complex
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
KR102372149B1 (ko)	2007-03-12	2022-03-07	인트라-셀룰라 써래피스, 인코퍼레이티드.	치환된 헤테로환 융합 감마-카르볼린 합성
EP2175724A4 (en)	2007-08-01	2010-09-15	Medivation Neurology Inc	METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY
PL2180844T3 (pl)	2007-08-02	2018-07-31	Insys Development Company, Inc.	Rozpylacz podjęzykowy z fentanylem
ES2421237T7 (es)	2007-08-15	2013-09-30	Arena Pharmaceuticals, Inc.	Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
US20090209608A1 (en)	2007-08-29	2009-08-20	Protia, Llc	Deuterium-enriched asenapine
US20090076159A1 (en)	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched eplivanserin
US8791138B2 (en)	2008-02-05	2014-07-29	Clera Inc.	Compositions and methods for alleviating depression or improving cognition
PL2262505T3 (pl)	2008-03-12	2015-04-30	Intra Cellular Therapies Inc	Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
EP3085231A1 (en)	2008-05-27	2016-10-26	Intra-Cellular Therapies, Inc.	Method and compositions for sleep disorders and other disorders
US8309772B2 (en)	2008-07-31	2012-11-13	Celanese International Corporation	Tunable catalyst gas phase hydrogenation of carboxylic acids
US20100159033A1 (en)	2008-09-29	2010-06-24	Auspex Pharmaceuticals, Inc.	Benzisoxazole modulators of d2 receptor, and/or 5-ht2a receptor
JP5989993B2 (ja) *	2008-12-06	2016-09-07	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
WO2011044019A1 (en)	2009-10-05	2011-04-14	Bristol-Myers Squibb Company	(R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
MX339805B (es)	2010-04-22	2016-06-10	Intra Cellular Therapies Inc	Compuestos organicos.
KR101946774B1 (ko)	2010-12-16	2019-02-11	선오비온 파마슈티컬스 인코포레이티드	설하 필름
US8697700B2 (en)	2010-12-21	2014-04-15	Albany Molecular Research, Inc.	Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8420057B2 (en)	2011-09-01	2013-04-16	Qualicaps, Inc.	Capsule having broad color spectrum
JP2015514135A (ja)	2012-04-14	2015-05-18	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規組成物および方法
UA116216C2 (uk)	2012-09-14	2018-02-26	Еббві Дойчланд Гмбх Унд Ко. Кг	Трициклічні хінолінові і хіноксалінові похідні
WO2014110322A2 (en) *	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
PT2968320T (pt)	2013-03-15	2021-01-28	Intra Cellular Therapies Inc	Compostos orgânicos
US9216175B2 (en)	2013-09-10	2015-12-22	Insys Pharma, Inc.	Sublingual buprenorphine spray
MX374480B (es)	2013-09-30	2025-03-06	Zoetis Services Llc	Formulaciones de espiro-isoxazolina de accion prolongada.
JP6475727B2 (ja)	2013-12-03	2019-02-27	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規方法
EP3125892A4 (en) *	2014-04-04	2017-12-27	Intra-Cellular Therapies, Inc.	Organic compounds
HUE065482T2 (hu)	2014-04-04	2024-05-28	Intra Cellular Therapies Inc	Deuterált heterociklus-fúzionált gamma-karbolinok mint 5-HT2A receptorok antagonistái
WO2015191554A1 (en)	2014-06-09	2015-12-17	Intra-Cellular Therapies, Inc.	Compounds and methods of use to treat schizophrenia
MY189352A (en)	2015-05-12	2022-02-07	Taiho Pharmaceutical Co Ltd	Crystals of Azabicyclic Compound
EP4512394A3 (en)	2015-06-03	2025-10-22	Triastek, Inc.	Dosage forms and use thereof
WO2017117514A1 (en) *	2015-12-31	2017-07-06	Tung Roger D	Deuterated iti-007
PL3838274T3 (pl)	2016-01-26	2024-04-02	Intra-Cellular Therapies, Inc.	Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
WO2017165843A1 (en)	2016-03-25	2017-09-28	Intra-Cellular Therapies, Inc.	Organic compounds
US20200392135A1 (en)	2016-03-25	2020-12-17	Intra-Cellular Therapies, Inc.	Organic compounds
US11331316B2 (en)	2016-10-12	2022-05-17	Intra-Cellular Therapies, Inc.	Amorphous solid dispersions
WO2018106916A1 (en) *	2016-12-07	2018-06-14	Concert Pharmaceuticals, Inc.	Deuterated quinoxaline compounds
WO2018175969A1 (en)	2017-03-24	2018-09-27	Intra-Cellular Therapies, Inc.	Novel compositions and methods
EP3609501A4 (en)	2017-04-10	2020-08-19	Dr. Reddy's Laboratories Limited	AMORPHIC FORM AND SOLID DISPERSIONS OF LUMATEPERONE P-TOSYLATE
AU2018307479B2 (en)	2017-07-26	2024-06-20	Intra-Cellular Therapies, Inc.	Organic compounds
US11427587B2 (en)	2017-07-26	2022-08-30	Intra-Cellular Therapies, Inc.	Organic compounds
CN119613404A (zh)	2018-03-23	2025-03-14	细胞内治疗公司	有机化合物
WO2019237037A1 (en)	2018-06-08	2019-12-12	Intra-Cellular Therapies, Inc.	Novel methods

2017
- 2017-03-24 WO PCT/US2017/024137 patent/WO2017165843A1/en not_active Ceased
- 2017-03-24 EP EP17771285.8A patent/EP3407889B1/en active Active
- 2017-03-24 SI SI201730872T patent/SI3407889T1/sl unknown
- 2017-03-24 HU HUE17771285A patent/HUE055334T2/hu unknown
- 2017-03-24 PT PT177712858T patent/PT3407889T/pt unknown
- 2017-03-24 CN CN201780017040.9A patent/CN108778277A/zh active Pending
- 2017-03-24 CN CN202111089807.3A patent/CN113754661A/zh active Pending
- 2017-03-24 IL IL304192A patent/IL304192B2/en unknown
- 2017-03-24 IL IL297676A patent/IL297676B2/en unknown
- 2017-03-24 MX MX2018011676A patent/MX387700B/es unknown
- 2017-03-24 PL PL17771285T patent/PL3407889T3/pl unknown
- 2017-03-24 KR KR1020227045681A patent/KR102684468B1/ko active Active
- 2017-03-24 IL IL314312A patent/IL314312A/en unknown
- 2017-03-24 EP EP21172297.0A patent/EP3888656A1/en active Pending
- 2017-03-24 US US16/088,397 patent/US10688097B2/en active Active
- 2017-03-24 AU AU2017238842A patent/AU2017238842B2/en active Active
- 2017-03-24 KR KR1020187030778A patent/KR102483124B1/ko active Active
- 2017-03-24 IL IL281050A patent/IL281050B2/en unknown
- 2017-03-24 RU RU2018137496A patent/RU2733975C2/ru active
- 2017-03-24 BR BR112018069594-7A patent/BR112018069594B1/pt active IP Right Grant
- 2017-03-24 CA CA3016353A patent/CA3016353C/en active Active
- 2017-03-24 DK DK17771285.8T patent/DK3407889T3/da active
- 2017-03-24 JP JP2018549879A patent/JP6686168B2/ja active Active
- 2017-03-24 ES ES17771285T patent/ES2879888T3/es active Active
2018
- 2018-08-29 IL IL261446A patent/IL261446B/en active IP Right Grant
- 2018-09-25 MX MX2021013564A patent/MX2021013564A/es unknown
2020
- 2020-04-01 JP JP2020065667A patent/JP6860724B2/ja active Active
- 2020-05-15 US US16/875,432 patent/US11096944B2/en active Active
2021
- 2021-03-26 JP JP2021053242A patent/JP7195362B2/ja active Active
- 2021-07-19 US US17/379,399 patent/US11723909B2/en active Active
2022
- 2022-12-13 JP JP2022198595A patent/JP7404491B2/ja active Active
2023
- 2023-06-22 US US18/339,956 patent/US12194044B2/en active Active
- 2023-12-13 JP JP2023209849A patent/JP2024037860A/ja active Pending
2024
- 2024-11-26 US US18/960,359 patent/US20250099471A1/en active Pending

Also Published As

Publication number	Publication date
IL304192B2 (en)	2024-12-01
JP6860724B2 (ja)	2021-04-21
US20250099471A1 (en)	2025-03-27
IL297676B1 (en)	2023-08-01
US11096944B2 (en)	2021-08-24
JP7195362B2 (ja)	2022-12-23
PL3407889T3 (pl)	2021-11-22
KR102483124B1 (ko)	2022-12-29
JP6686168B2 (ja)	2020-04-22
JP2019512525A (ja)	2019-05-16
US10688097B2 (en)	2020-06-23
US20220008423A1 (en)	2022-01-13
IL297676B2 (en)	2023-12-01
IL281050B2 (en)	2023-04-01
HUE055334T2 (hu)	2021-11-29
KR20180128453A (ko)	2018-12-03
US20230346787A1 (en)	2023-11-02
WO2017165843A1 (en)	2017-09-28
US11723909B2 (en)	2023-08-15
US12194044B2 (en)	2025-01-14
JP7404491B2 (ja)	2023-12-25
US20200352949A1 (en)	2020-11-12
US20190231780A1 (en)	2019-08-01
JP2021100970A (ja)	2021-07-08
EP3407889A1 (en)	2018-12-05
JP2020114856A (ja)	2020-07-30
KR20230003461A (ko)	2023-01-05
IL304192A (en)	2023-09-01
EP3407889B1 (en)	2021-05-19
BR112018069594B1 (pt)	2023-12-05
AU2017238842A1 (en)	2018-10-11
EP3888656A1 (en)	2021-10-06
CA3016353A1 (en)	2017-09-28
CA3016353C (en)	2021-04-27
JP2024037860A (ja)	2024-03-19
IL261446B (en)	2021-03-25
ES2879888T3 (es)	2021-11-23
AU2017238842B2 (en)	2019-06-20
IL281050A (en)	2021-04-29
SI3407889T1 (sl)	2021-09-30
KR102684468B1 (ko)	2024-07-11
MX2018011676A (es)	2018-12-19
IL314312A (en)	2024-09-01
MX2021013564A (es)	2021-12-10
PT3407889T (pt)	2021-07-14
CN108778277A (zh)	2018-11-09
IL304192B1 (en)	2024-08-01
DK3407889T3 (da)	2021-08-09
MX387700B (es)	2025-03-18
EP3407889A4 (en)	2019-03-13
RU2733975C2 (ru)	2020-10-08
IL297676A (en)	2022-12-01
IL281050B (en)	2022-12-01
JP2023030006A (ja)	2023-03-07
CN113754661A (zh)	2021-12-07
BR112018069594A2 (pt)	2019-01-29
IL261446A (en)	2018-10-31
RU2018137496A (ru)	2020-04-27

Publication	Publication Date	Title
BR112019009389A2 (ru)	2019-07-23
BR122021013712A2 (ru)	2019-11-19
BR122020022459A2 (ru)	2019-06-25
BR202016025584U2 (ru)	2018-05-29
BR202016021516U2 (ru)	2018-04-03
CN303573034S (ru)	2016-01-27
CN303537770S (ru)	2016-01-06
CN303535547S (ru)	2016-01-06
CN303536129S (ru)	2016-01-06
CN303536208S (ru)	2016-01-06
CN303536232S (ru)	2016-01-06
CN303536246S (ru)	2016-01-06
CN303536269S (ru)	2016-01-06
CN303536362S (ru)	2016-01-06
CN303536516S (ru)	2016-01-06
CN303536549S (ru)	2016-01-06
CN303536736S (ru)	2016-01-06
CN303537271S (ru)	2016-01-06
CN303537358S (ru)	2016-01-06
CN303537427S (ru)	2016-01-06
CN303537519S (ru)	2016-01-06
CN303537566S (ru)	2016-01-06
CN303537608S (ru)	2016-01-06
CN303537689S (ru)	2016-01-06
CN303537691S (ru)	2016-01-06